| Pharmaceutical Information |
| Drug Name |
Icosapent |
| Drug ID |
BADD_D01125 |
| Description |
Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. |
| Indications and Usage |
EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy. |
| Marketing Status |
approved; nutraceutical |
| ATC Code |
Not Available |
| DrugBank ID |
DB00159
|
| KEGG ID |
D08061
|
| MeSH ID |
D015118
|
| PubChem ID |
446284
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| UNII |
AAN7QOV9EA
|
| Synonyms |
Eicosapentaenoic Acid | 5,8,11,14,17-Eicosapentaenoic Acid | Eicosapentanoic Acid | Acid, Eicosapentanoic | omega-3-Eicosapentaenoic Acid | omega 3 Eicosapentaenoic Acid | Timnodonic Acid | Icosapent | 5,8,11,14,17-Icosapentaenoic Acid |
|
| Chemical Information |
| Molecular Formula |
C20H30O2 |
| CAS Registry Number |
10417-94-4 |
| SMILES |
CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
